TSL2109胶囊是由江苏帝益和中国药科大学联合申报的具有全新结构的双靶点小分子抑制剂，可通过选 择性抑制双靶点下游信号通路，阻滞肿瘤细胞周期、诱导肿瘤细胞凋亡，发挥双靶点协同杀伤肿瘤细胞 的作用。 天士力（600535）(600535.SH)发布公告，近日，公司全资子公司江苏天士力帝益药业有限公司(简称"江 苏帝益")收到国家药品监督管理局核准签发关于TSL2109胶囊用于晚期实体瘤的《药物临床试验批准通 知书》。 ...

Core Viewpoint - Tianshili (600535.SH) announced that its wholly-owned subsidiary, Jiangsu Tianshili Diyi Pharmaceutical Co., Ltd. (referred to as "Jiangsu Diyi"), has received approval from the National Medical Products Administration for the clinical trial of TSL2109 capsules for advanced solid tumors [1] Group 1 - TSL2109 capsules are a novel dual-target small molecule inhibitor developed in collaboration with China Pharmaceutical University [1] - The drug works by selectively inhibiting downstream signaling pathways of the two targets, blocking the tumor cell cycle and inducing tumor cell apoptosis [1] - TSL2109 aims to synergistically kill tumor cells through its dual-target mechanism [1]

天士力公告，近日全资子公司江苏帝益收到国家药品监督管理局核准签发关于 TSL2109 胶囊用于晚期 实体瘤的《药物临床试验批准通知书》。TSL2109 胶囊是江苏帝益和中国药科大学联合申报的具有全 新结构的双靶点小分子抑制剂，已累计投入研发人民币 2462.51万元。新药研发过程存在不确定性，未 来产品市场竞争形势也将发生变化。 ...